56:57
0
PINBridging Guidelines: Evaluating International Breast Cancer Consensus in the Canadian Context
With Dr. Paolo Tarantino & Dr. Nathaniel Bouganim
CANADIAN Perspective Series
Bridging Guidelines: Evaluating International Breast Cancer Consensus in the Canadian Context
CANADIAN Perspective Series
Managing HER2+ Brain Metastases: Challenges and Opportunities - A Canadian perspective
CLINICAL IMPACT Series
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
CLINICAL IMPACT Series
CLINICAL IMPACT - Ask the experts: Advancing Clinical Research in Breast Cancer
CLINICAL IMPACT Series
CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
CANADIAN Perspective Series
Managing HER2+ Brain Metastases: Challenges and Opportunities - A Canadian perspective
With Katarzyna Jerzak, MD & Nancy U. Lin, MD
CLINICAL IMPACT Series
CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
CLINICAL IMPACT - Ask the experts: Advancing Clinical Research in Breast Cancer
Insights into Phases, Endpoints and Patient-Centric Strategies with Dr. Jamil Asselah and Dr. Véronique Diéras
ESMO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Kim Ma
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
With Dr. Jamil Asselah, Dr. Tarek Hijal, Pr. Sylvie Lambert, Dr. Bertrand Lebouché & John Ioculano
ASCO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Nicholas Meti & Dr. Khashayar Esfahani
CLINICAL IMPACT - Genetic testing for breast cancer patients in Quebec: Why, how and whom?
Session moderated by Dr. Rami Younan, featuring Nathalie Bolduc, Genetic Counsellor and Dr. Julie Lemieux, Hematologist and Medical Oncologist.
SABCS 2022 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Sara Soldera and Dr. Julie Lemieux
ESMO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Nicholas Meti
ASCO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Khashayar Esfahani & Dr. Isabelle Gingras
CLINICAL IMPACT SERIES: SABCS 2021 - Metastatic Breast Cancer
Presentations review with Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Neo Adjuvant Breast Cancer
Presentations review with Dr. Rami Younan, MD, FRCSC
CLINICAL IMPACT SERIES: SABCS 2021 - Adjuvant Breast Cancer for ER+ HER2-, and ER-
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC
Dr. Tarantino - DESTINY BREAST
Q4: What is the impact of DESTINY BREAST trial on triple-negative breast cancer?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q3: Any other AEs to be on a look out for?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
SABCS 2023
SABCS 2023 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2023 data in Breast Cancer with Dr. Rami Younan, Dr. Julie Lemieux & Dr. Kim Ma
WOO Series
WOO SERIES - Patients perspectives on WOOs as a clinical research tool
Interview of Patient Carol Gordon, CPA, CFA by Dr.Angel Arnaout, MD MSC FRCSC MBA
WOO SERIES - How do WOOs contribute to research – individually and collectively, why are they valuable?
With Dr. Melanie Spears
WOO SERIES - WOO presurgical trials - a Clinician’s perspective
With Dr. Angel Arnaout MD MSC FRCSC MBA
ASCO 2022
Molecular Profiling; From prognosis to prediction – remaining questions
Scientific Presentation with Prof. John Bartlett
The success of ADCs raises questions about patient selection
Scientific Presentation with Prof. John Bartlett
AI Series
AI SERIES: Precision medicine in practice - diagnostic algorithms & geroncology
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Precision medicine cancer therapeutics, HR sensitive BC and AI challenges
Presentation by Pr. John Robertson MD
AI SERIES - AI assisted drug development and repurposing in Breast Cancer
With Dr. Evelyne Yehudit Bischof
AI SERIES - Personalized vs precision medicine, clinical applicability
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Do we need Artificial Intelligence for Precision Medicine?
Presentation by Pr. Robert Clarke Ph.D., D.Sc.
COVID Impact
ESMO-2020 - Expected medium and long-term impact of the COVID-19 outbreak in Oncology
Presentation by Professor Guy Jerusalem
A Global Collaborative study looking at the Impact of COVID-19 Pandemic on Cancer Care
With Dr. Abdul-Rahman Jazieh
COVID-19 pandemic and Changes in Breast Cancer Management in the UK
With Professor John Robertson
OICR Series
Predicting Response to Anthracyclines
Presentation by Dr. Melanie Spears, PhD
Congress programs
Characterization of immune “hot” hormone receptor positive breast cancer
Presentation by Dr. Melanie Spears
ESMO-2020 - Adjuvant abemaciclib reduces relapse risk in high-risk early breast cancer (MonarchE)
Presentation by Professor Stephen Johnston
Targeting novel pathways in breast cancer
With Jorge S Reis-Filho, MD PhD FRCPath
LBA8 KEYNOTE-522 study and the LBA9 Phase 3 BROCADE study
Late breaking abstracts discussion:
Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer.
With Dr. Judith Balmaña
HER2 overexpressing breast cancer
Novel therapeutic strategies
What’s needed next to meet the challenges in ER+ve breast cancer care?
A researcher perspective
HER2 Positive Breast Cancer: A Clinical Update since the St. Gallen International Breast Conference in 2017
with Martine J. Piccart, MD, PhD
New Insights in Luminal Breast Cancer
with Matthew J. Ellis, MB, BChir, BSc, PhD
Targeting Immune Pathways in Breast Cancer
with Sherene Loi, MD, PhD
All Programs
Bridging Guidelines: Evaluating International Breast Cancer Consensus in the Canadian Context
With Dr. Paolo Tarantino & Dr. Nathaniel Bouganim
Managing HER2+ Brain Metastases: Challenges and Opportunities - A Canadian perspective
With Katarzyna Jerzak, MD & Nancy U. Lin, MD
CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
CLINICAL IMPACT - Ask the experts: Advancing Clinical Research in Breast Cancer
Insights into Phases, Endpoints and Patient-Centric Strategies with Dr. Jamil Asselah and Dr. Véronique Diéras
SABCS 2023 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2023 data in Breast Cancer with Dr. Rami Younan, Dr. Julie Lemieux & Dr. Kim Ma
Q4: What is the impact of DESTINY BREAST trial on triple-negative breast cancer?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q3: Any other AEs to be on a look out for?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
ESMO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Kim Ma
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
With Dr. Jamil Asselah, Dr. Tarek Hijal, Pr. Sylvie Lambert, Dr. Bertrand Lebouché & John Ioculano
ASCO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Nicholas Meti & Dr. Khashayar Esfahani
CLINICAL IMPACT - Genetic testing for breast cancer patients in Quebec: Why, how and whom?
Session moderated by Dr. Rami Younan, featuring Nathalie Bolduc, Genetic Counsellor and Dr. Julie Lemieux, Hematologist and Medical Oncologist.
SABCS 2022 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Sara Soldera and Dr. Julie Lemieux
WOO SERIES - Patients perspectives on WOOs as a clinical research tool
Interview of Patient Carol Gordon, CPA, CFA by Dr.Angel Arnaout, MD MSC FRCSC MBA
WOO SERIES - How do WOOs contribute to research – individually and collectively, why are they valuable?
With Dr. Melanie Spears
WOO SERIES - WOO presurgical trials - a Clinician’s perspective
With Dr. Angel Arnaout MD MSC FRCSC MBA
ESMO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Nicholas Meti
ASCO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Khashayar Esfahani & Dr. Isabelle Gingras
Molecular Profiling; From prognosis to prediction – remaining questions
Scientific Presentation with Prof. John Bartlett
The success of ADCs raises questions about patient selection
Scientific Presentation with Prof. John Bartlett
Predicting Response to Anthracyclines
Presentation by Dr. Melanie Spears, PhD
CLINICAL IMPACT SERIES: SABCS 2021 - Metastatic Breast Cancer
Presentations review with Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Neo Adjuvant Breast Cancer
Presentations review with Dr. Rami Younan, MD, FRCSC
CLINICAL IMPACT SERIES: SABCS 2021 - Adjuvant Breast Cancer for ER+ HER2-, and ER-
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC
AI SERIES: Precision medicine in practice - diagnostic algorithms & geroncology
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Precision medicine cancer therapeutics, HR sensitive BC and AI challenges
Presentation by Pr. John Robertson MD
AI SERIES - AI assisted drug development and repurposing in Breast Cancer
With Dr. Evelyne Yehudit Bischof
AI SERIES - Personalized vs precision medicine, clinical applicability
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Do we need Artificial Intelligence for Precision Medicine?
Presentation by Pr. Robert Clarke Ph.D., D.Sc.
Characterization of immune “hot” hormone receptor positive breast cancer
Presentation by Dr. Melanie Spears
ESMO-2020 - Expected medium and long-term impact of the COVID-19 outbreak in Oncology
Presentation by Professor Guy Jerusalem
A Global Collaborative study looking at the Impact of COVID-19 Pandemic on Cancer Care
With Dr. Abdul-Rahman Jazieh
ESMO-2020 - Adjuvant abemaciclib reduces relapse risk in high-risk early breast cancer (MonarchE)
Presentation by Professor Stephen Johnston
COVID-19 pandemic and Changes in Breast Cancer Management in the UK
With Professor John Robertson
Targeting novel pathways in breast cancer
With Jorge S Reis-Filho, MD PhD FRCPath
LBA8 KEYNOTE-522 study and the LBA9 Phase 3 BROCADE study
Late breaking abstracts discussion:
Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer.
With Dr. Judith Balmaña
HER2 overexpressing breast cancer
Novel therapeutic strategies
What’s needed next to meet the challenges in ER+ve breast cancer care?
A researcher perspective
Educational Presentation summarizing “Neoadjuvant vs adjuvant approaches in early TNBC”
With Javier Cortes, MD PhD
Using integrated OMICS and deep targeted sequencing as novel diagnostic processes in cancer
with John Bartlett, Ph.D, FRCPath
HER2 Positive Breast Cancer: A Clinical Update since the St. Gallen International Breast Conference in 2017
with Martine J. Piccart, MD, PhD
New Insights in Luminal Breast Cancer
with Matthew J. Ellis, MB, BChir, BSc, PhD
Targeting Immune Pathways in Breast Cancer
with Sherene Loi, MD, PhD